生物试剂
>
生化试剂
>
信号通路
> Pivanex
加入收藏 取消收藏

Pivanex  

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：50mg 250mg 1g in glass bottle
溶解性：溶于DMSO（≥ 100 mg/mL）
产品描述：基本信息 产品编号：P10839 产品名称：Pivanex CAS: 122110-53-6   储存条件 粉末 -20℃ 四年 分子式： C10H18O4 分子量 202.25 化学名：  Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester   Solubility (25°C)   体外 DMSO ≥100mg/mL (494.44mM) Ethanol   Water   体内 现配现用   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 4.9444mL 24.7219mL 49.4438mL 5mM 0.9889mL 4.9444mL 9.8888mL 10mM 0.4944mL 2.4722mL 4.9444mL   生物活性 产品描述 丁酸的衍生物，是口服有效的 HDAC 抑制剂。Pivanex 可下调 bcr-abl 蛋白，增强凋亡 (apoptosis)。 靶点/IC50 HDAC Bcr-Abl   体外研究 Pivanex (100-500μM) exhibits significant anti-proliferation activity in K562 cells. Pivanex (100-500μM) also enhances apoptosis and caspase activity in K562 cells. Pivanex (200μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle. Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Cell Viability Assay Cell Line: K562 cells. Concentration: 100-500μM. Incubation Time: 24 hours. Result: Reduced the number of K562 viable cells significantly. 100μM Pivanex with 0.125 or 0.25μM STI571 reduced the number of viable cells synergistically. Apoptosis Analysis Cell Line: K562 cells. Concentration: 100-500μM. Incubation Time: 6-72 hours. Result: Increased the number of K562 apoptotic cells significantly. Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500μM.   体内研究 Pivanex (AN9, 200mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss. Animal Model: SMN7 SMA mice (SMN2+/+; SMN7+/+; mSmn−/−) [3] . Dosage: 200mg/kg. Administration: Oral administration, b.i.d, at 09.00 and 17.00 daily Result: Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.
保存条件：-20℃

猜你喜欢